Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Adaptimmune Announces Exclusive License with Life Technologies

Published: Monday, January 07, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
The exclusive license secures a critical component for commercial development of modified T cells.

Adaptimmune announces that it has secured an exclusive commercial license from Life Technologies Corporation for its intellectual property portfolio for methods of expanding and activating T cells transduced with engineered T cell receptors (TCR). Life’s Dynabeads® CD3/CD28 CTS™ are the only GMP-grade reagents commercially available for use in clinical trials practicing these patented methods for the rapid expansion of autologous T cells in T cell therapy.

Background to the exclusive license
Adaptimmune’s technology is based on enhancing the power of the T cell receptor (TCR) on killer T cells.  This involves taking the patient’s own T cells, genetically modifying them to present the selected TCR and then re-infusing the T cells into the patient. A critical step in this process is the stimulation and expansion of the T cells prior to re-infusion. Since Life Technologies’ beads are the only GMP-grade reagents commercially available for this patented process, today’s deal means that Adaptimmune has secured exclusive commercial access to the technology and the underlying manufacturing processes needed for obtaining regulatory approval of expansion of T cells carrying TCRs. 

Life Technologies has developed a considerable portfolio of intellectual property relating to the use of anti-CD3/anti-CD28 antibody-coated magnetic beads for expansion of autologous T cells. The license agreements give Adaptimmune exclusive commercial rights to use Life’s beads and the processes for transduced TCRs used in T cell therapy. It does not affect the use of Life’s beads in other fields or for non-profit, non-commercial, or academic use.

A landmark  deal for Adaptimmune
Adaptimmune has a number of programmes in the clinic with TCR-modified T cells, which rely on Life Technologies’ patented methods, as well as a pipeline of new TCRs at the pre-clinical stage. In December 2012, Adaptimmune announced encouraging preliminary results from its multiple myeloma trial at the American Society of Hematology Conference. Adaptimmune is also investigating other cancers with its leading TCR, which targets an antigen known as NY-ESO. 

Today’s announcement is another step in Adaptimmune’s continuing route to exclusive commercialization of its products in this new field of autologous TCR-transduced T cell therapy, including establishing consistent GMP manufacturing of expanded T cells carrying TCRs for all later-stage studies and for commercialization. 

Mr. James Noble, Chief Executive Officer of Adaptimmune, commented: “This is a landmark deal for Adaptimmune. We have been pioneers in the field of engineering T cell receptors for many years through the expertise of our CSO, Dr. Bent Jakobsen. This deal takes us to the next stage by securing a long-term and exclusive route to manufacturing our products for late-stage clinical studies and, if those 

trials are successful, for the market. Adaptimmune can now not only create TCRs for T cell therapy, but also exclusively use the intellectual property needed for the manufacturing process and commercialization.” 

“Life Technologies believes in the promise of cellular and genomic medicine and is dedicated to nurturing innovation in this emerging therapeutic field,” said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. “The partnership with Adaptimmune demonstrates Life’s commitment to deliver technologies that integrate the delivery of next generation therapies currently under development to treat the most critically ill patients.”

Financial terms of the licensing deal are not disclosed. Adaptimmune was assisted in negotiating the deal by Vedder Price PC.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Tuesday, July 21, 2015
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Tuesday, July 21, 2015
Adaptimmune Appoints Lawrence M. Alleva to its Board of Directors
Lawrence M. Alleva will join the Board as an independent, non-executive director.
Wednesday, March 11, 2015
Adaptimmune Strengthens Management Team with Key Executive Hires
Adaptimmune has strengthened its senior management team with the appointment of Dr. Rafael Amado, as Chief Medical Officer, and Adrian (Ad) Rawcliffe, as Chief Financial Officer.
Wednesday, March 04, 2015
Adaptimmune Announces Interim Results from Pilot Trial of NY-ESO T Cells
Study reports encouraging response rate and safety profile.
Friday, October 17, 2014
Adaptimmune Secures $104 Million in Series A Financing
Company will use funding to advance programmes in multiple cancer indications.
Friday, September 26, 2014
Adaptimmune Named as One of “Fierce 15” Biotech Companies of 2014
Company has created T-cell receptors which are deployed to target NY-ESO-1.
Tuesday, September 23, 2014
Adaptimmune Announces Full-time Appointment of James Noble as CEO
Appointment will become effective from 31st March.
Thursday, March 27, 2014
Adaptimmune Awarded £2.1m from the Biomedical Catalyst Fund
The prestigious award supports Adaptimmune’s clinical pipeline expansion.
Tuesday, March 25, 2014
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells
Study continues to report encouraging response rates, safety and proof of mechanism.
Thursday, December 12, 2013
Interim Results from Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
Adaptimmune announces that study continues to report encouraging response rates, safety and proof of mechanism.
Tuesday, December 10, 2013
Adaptimmune Appoints Chairman of the Board
Dr Jonathan Knowles has been appointed as the new executive Chairman of the Board of Directors with immediate effect.
Thursday, November 21, 2013
Adaptimmune Announces Opening of Phase I/IIa Clinical Trial
Adaptimmune announced that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer.
Thursday, July 25, 2013
NeoStem’s Subsidiary, PCT Enters into Services Agreement with Adaptimmune
PCT to provide cell product development and manufacturing for Adaptimmune’s clinical trials.
Thursday, January 24, 2013
NeoStem Subsidiary Enters Into a Cell Therapy Manufacturing Services Agreement with Adaptimmune
PCT to provide cell product development and manufacturing for Adaptimmune’s clinical trials.
Monday, January 21, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!